Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 54, 2020 - Issue 4
Journal homepage
142
Views
2
CrossRef citations to date
0
Altmetric
Articles

A prospective study of a urine and plasma biomarker test for the prediction of gleason ≥3 + 4 prostate cancer in a mixed cohort

Mads Hvid PoulsenDepartment of Urology, Odense University Hospital, Odense, Denmark; ;Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; ;Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Correspondence[email protected]
,
Søren FeddersenDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark; ;Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark;
,
Maher AlbitarResearch and Development Department, NeoGenomics Laboratories, Carlsbad, CA, USA
,
Charlotte Aaberg PoulsenDepartment of Urology, Odense University Hospital, Odense, Denmark;
,
Martin LundDepartment of Urology, Odense University Hospital, Odense, Denmark;
,
Torben Brøchner PedersenDepartment of Urology, Odense University Hospital, Odense, Denmark;
,
Mike Allan MortensenDepartment of Urology, Odense University Hospital, Odense, Denmark; ;Department of Clinical Research, University of Southern Denmark, Odense, Denmark;
&
Lars LundDepartment of Urology, Odense University Hospital, Odense, Denmark; ;Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark; ;Department of Clinical Research, University of Southern Denmark, Odense, Denmark;
show all
Pages 323-327 | Received 29 Oct 2019, Accepted 10 Jun 2020, Published online: 01 Jul 2020

References

  • Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol. 2006;7(5):355–362.
  • Berman DM, Epstein JI. When is prostate cancer really cancer? Urol Clin North Am. 2014;41(2):339–346.
  • Borghesi M, Ahmed H, Nam R, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol. 2017;71(3):353–365.
  • Artherholt SB, Fann JR. Psychosocial care in cancer. Curr Psychiatry Rep. 2012;14(1):23–29.
  • Coyle C, Morgan E, Drummond FJ, et al. Do men regret prostate biopsy: results from the PiCTure study. BMC Urol. 2017;17(1):11.
  • Oba A, Nakaya N, Saito-Nakaya K, et al. Psychological distress in men with prostate cancer and their partners before and after cancer diagnosis: a longitudinal study. Jpn J Clin Oncol. 2017;47(8):735–742.
  • Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4(3):e003901.
  • Petrelli F, Vavassori I, Cabiddu M, et al. Predictive factors for reclassification and relapse in prostate cancer eligible for active surveillance: a systematic review and meta-analysis. Urology. 2016;91:136–142.
  • Al-Hussain TO, Nagar MS, Epstein JI. Gleason pattern 5 is frequently underdiagnosed on prostate needle-core biopsy. Urology. 2012;79(1):178–181.
  • Albitar M, Ma W, Lund L, et al. A multi-center prospective study to validate an algorithm using urine and plasma biomarkers for predicting gleason ≥3 + 4 prostate cancer on biopsy. J Cancer. 2017;8(13):2554–2560.
  • Albitar M, Ma W, Lund L, et al. Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer. Prostate. 2018;78(4):294–299.
  • Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245–255.
  • Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31(11):1428–1434.
  • Guyon IFH, Choppa P, et al. A four-gene expression signature for prostate cancer cells consisting of UAP1, PDLIM5, IMPDH2, and HSPD1. UroToday Int. 2009;2:3834–3844.
  • Albitar M, Ma W, Lund L, et al. Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System. J Cancer. 2016;7(3):297–303.
  • Ma W, Diep K, Fritsche HA, et al. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers. Genet Test Mol Biomarkers. 2014;18(3):156–163.
  • D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998;280(11):969–974.
  • Cucchiara V, Cooperberg MR, Dall'Era M, et al. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73(4):572–582.
  • Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis. 2017;20(1):12–19.
  • Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [–2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate specific antigen range. J Urol. 2011;185(5):1650–1655.
  • Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med. 2008;6:19.
  • Nordstrom T, Vickers A, Assel M, et al. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015;68(1):139–146.
  • Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975–5979.
  • Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–648.
  • Donovan MJ, Noerholm M, Bentink S, et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015;18(4):370–375.
  • Leyten GH, Hessels D, Smit FP, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res. 2015;21(13):3061–3070.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.